bearish
The Risks of High Expectations for Biosimilars
252 Views11 Oct 2015 04:02
Celltrion trades at a premium valuation (35x 2016 estimated earnings) based on high expectations for its biosimilar (copycats of biotech) products....
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
- Okja: The Fight Between Netflix Vs. CJ CGV05 Jun 2017
- Netflix & Amazon Expand in Korea – Not a Coincidence20 Jan 2016
- Thoughts on Amazon –What Does Its Valuation Tells Us?01 Dec 2015
- The Risks of High Expectations for Biosimilars11 Oct 2015
x